Fig. 1.

A schematic of the Markov model, indicating patient care strategies and possible transitions to cardiovascular disease and adverse event states. Five care strategies were considered: do-not-treat, no statin therapy; test-and-MST (moderate-intensity statin for those in the top decile of LDL-P levels); MST (moderate-intensity statin for all); test-and-HST (high-intensity statin for those in the top decile of LDL-P levels and moderate-intensity statin for all others); and HST (high-intensity statin for all). Abbreviations: MST, moderate-intensity statin therapy; HST, high-intensity statin therapy; MI, myocardial infarction; RVSC, revascularization, PCI, percutaneous intervention; CABG, coronary artery bypass surgery; mild AE, mild adverse events (myalgia); severe AE, (myopathy, rhabdomyolysis or hemorrhagic stroke); M-CVD, multiple CVD state. Green circles denote chance outcomes within a cycle; red triangles are terminal states. In all scenarios, patients enter the model in the disease-free state. In the first 1-year cycle individuals either remain in the disease-free state or experience a clinical event (MI, stroke, CABG, PCI, mild or severe AE, diabetes or death)